What is Korro Bio Retained Earnings?
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Korro Bio's retained earnings for the quarter that ended in Jun. 2023 was $-139.09 Mil.
Korro Bio's quarterly retained earnings
declined
from Jun. 2022 ($0.00 Mil) to Dec. 2022 ($-101.83 Mil) and
declined
from Dec. 2022 ($-101.83 Mil) to Jun. 2023 ($-139.09 Mil).
Korro Bio's annual retained earnings
declined
from Dec. 2021 ($-43.80 Mil) to Dec. 2022 ($-101.83 Mil) and
declined
from Dec. 2022 ($-101.83 Mil) to Dec. 2023 ($-183.01 Mil).
Korro Bio Retained Earnings Historical Data
The historical data trend for Korro Bio's Retained Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Korro Bio Retained Earnings Chart
|
Korro Bio Annual Data
|
|
Trend |
Dec21 |
Dec22 |
Dec23 |
| Retained Earnings |
|
-43.80 |
-101.83 |
-183.01 |
|
Korro Bio Semi-Annual Data
|
|
Dec21 |
Jun22 |
Dec22 |
Jun23 |
Dec23 |
| Retained Earnings |
-43.80 |
- |
-101.83 |
-139.09 |
-183.01 |
Korro Bio Retained Earnings Calculation
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
Korro Bio (NAS:KRRO) Retained Earnings Explanation
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Korro Bio (Korro Bio) Business Description
Traded in Other Exchanges
N/A
Address
One Kendall Square, Suite 6-401, Building 600-700, Cambridge, MA, USA, 02139
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
Executives
| David L. Lucchino |
director, officer: President and CEO |
C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801 |
| Rick Yang |
10 percent owner |
2855 SAND HILL ROAD, MENLO PARK CA 94025 |
| Edward T Mathers |
10 percent owner |
C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
| Nessan Bermingham |
director |
890 WINTER STREET, WALTHAM MA 02451 |
| Atlas Venture Associates Xi, Llc |
10 percent owner |
400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
| Atlas Venture Associates Xi, L.p. |
10 percent owner |
400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
| New Enterprise Associates 17, L.p. |
10 percent owner |
1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
| Nea Partners 17, L.p. |
10 percent owner |
1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
| Nea 17 Gp, Llc |
10 percent owner |
1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
| Atlas Venture Fund Xi, L.p. |
10 percent owner |
400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
| Atlas Venture Opportunity Fund Ii, L.p. |
10 percent owner |
300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
| Atlas Venture Associates Opportunity Ii, Llc |
10 percent owner |
300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
| Atlas Venture Associates Opportunity Ii, Lp |
10 percent owner |
300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
| Steve Colletti |
officer: Chief Scientific Officer |
C/O KORRO BIO, INC., ONE KENDALL SQUARE, BUILDING 600-700, CAMBRIDGE MA 02139 |
| Shelby J. Walker |
officer: See Remarks |
C/O KORRO BIO, INC., ONE KENDALL SQUARE, BUILDING 600-700, CAMBRIDGE MA 02139 |
Korro Bio (Korro Bio) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KRRO has been successfully added to your